SynthesisFrontiers in neurology2025
Tenecteplase versus alteplase in bridging therapy in patients with large vessel occlusion stroke: a meta-analysis.
Synthesis in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Currently, for patients with large-vessel occlusion (LVO) strokes, the standard treatment approach involves using alteplase (ALT) as a bridge to endovascular mechanical thrombectomy (MT). Tenecteplase (TNK) is a novel fibrinolytic agent. Our research is focused on evaluating and comparing the efficacy and safety of TNK and ALT in patients with acute ischemic stroke (AIS) and large-vessel occlusion before they undergo MT. Methods: The study's research plan was registered in the International Prospective Register of Systematic Reviews (PROSPERO) under the number CRD42025643339. The entire process adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines, guaranteeing high-quality and standardized reporting and analysis. Results: In total, 7 studies involving 4,580 patients were incorporated. Patients treated with TNK exhibited comparable rates of functional independence at 90 days (odds ratio 1.23, 95% confidence interval 0.90-1.68, Conclusion: Regarding of functional independence at 90 days, post-MT recanalization, sICH and 90-day mortality in AIS patients undergoing MT, there were essentially no difference between TNK and ALT. However, TNK might be more effective than ALT in achieving early recanalization, and it may also reduce the risks of ICH. Clinical trial registration: Unique Identifier: CRD42025643339, Publicly Accessible URL: https://www.crd.york.ac.uk/PROSPERO/.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.